glp-1 and levothyroxine receptors (GLP-1R) are expressed in premalignant lesions in human Tirzepatide and levothyroxine: guide to

No typing, no second-guessing

This side effect has not been reported at similar rates with semaglutide or tirzepatide and appears to be related to the glucagon receptor activation component unique to retatrutide

[DOI] [PubMed] [Google Scholar] 12.Kreymann B, Williams G, Ghatei MA, Bloom SR

26 Clinical data on GLP-1 receptor agonists and pancreatitis occurrence Postlethwaite, et al 7 reported that, among 2,245 patients with obesity (mean body mass index 39.7 kg/m2 ) who started GLP-1 receptor agonist therapy, 49 (2.2%) developed acute pancreatitis

The GLP-1 Protein Shake Builder is a dietitian-created tool designed for low appetite, nausea, and protein gaps common challenges while using GLP-1 medications

The injectable versus oral peptide comparison is also relevant here, because some researchers transitioning from oral semaglutide may have different GLP-1 receptor adaptation profiles than those coming from injectable formulations